ERBB2 and breast carcinoma: In this single–centered retrospective study, we evaluated the treatment efficacy and prognosis of patients with luminal B (HER–2 negative) breast cancer in our hospital, investigated the correlation between AR and its associated indicators with patient survival, and aimed to find a prognostic and predictive cutoff value.